MedTrace Logo

Serum Biomarkers for Portal Hypertension in Cirrhosis (Pan-CHESS1802)

NCT03713606 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2021-08-17

No results posted yet for this study

Summary

This is a prospective, multi-center diagnostic trial conducted at 6 liver centers in China designed to study the correlation between serum biomarkers associated with endothelial dysfunction and immune inflammation and hepatic venous pressure gradient in cirrhosis.

Conditions

  • Hypertension, Portal

Interventions

PROCEDURE

HVPG measurement

HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter.

Sponsors & Collaborators

  • Beijing YouAn Hospital

    collaborator OTHER

  • Shandong Provincial Hospital

    collaborator OTHER_GOV

  • Beijing Shijitan Hospital, Capital Medical University

    collaborator OTHER

  • Beijing Friendship Hospital

    collaborator OTHER

  • Xingtai People's Hospital

    collaborator OTHER

  • Beijing 302 Hospital

    collaborator OTHER

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Principal Investigators

  • Xiaolong Qi, M.D. · Nanfang Hospital, Southern Medical University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-30
Primary Completion
2022-01-31
Completion
2022-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03713606 on ClinicalTrials.gov